A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
← catalyst calendarNCT06984627 · readout in 6 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
30estimated
Sites
15
Countries
Canada, Germany, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-02 | actual | When the study began enrolling |
| Primary completion | 2026-08-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Graves' Disease
Interventions
- Drug: Rilzabrutinib dose 1 — also filed as SAR444671
- Drug: Rilzabrutinib dose 2 — also filed as SAR444671
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in FT4 levels
measured At Week16
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed